Lifecare ASA: Share capital increase and warrants registered

Reference is made to the stock exchange announcement published by Lifecare ASA (“Lifecare” or the “Company”) on 14 June 2024 regarding the final results of the partially underwritten rights issue of new shares in the Company (the “Rights Issue”).

The share capital increase pertaining to the issuance of 59,038,955 new shares in the Rights Issue has now been registered with the Norwegian Register of Business Enterprises. The Company’s new share capital is NOK 77,561,878.80 divided on 193,904,697 shares, each with a par value of NOK 0.40.

The subscribers in the Rights Issue were allocated one warrant for every two shares allocated to, and paid by, them in the Rights Issue (the “Warrants“). Further, Munkekullen 5 Förvaltning AB and Buntel AB, having underwritten a total of NOK 50 million of the Rights Issue, were allocated a total of 25,000,000 warrants at equal terms to the Warrants, as compensation for their underwriting commitment (the “Additional Warrants“). The issuance of in total 29,519,478 Warrants and 25,000,000 Additional Warrants has now been registered with the Norwegian Register of Business Enterprises.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM“) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR“) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.